Immunocore Completes Enrollment in Pivotal TEBE-AM Melanoma Trial, Data Expected by End of 2026
IMCR sits 18% above its 52-week low of $27.555.
Summary
Immunocore has reached target enrollment of 540 patients in its registrational Phase 3 TEBE-AM trial of KIMMTRAK (tebentafusp) in previously treated advanced melanoma. This is a key operational milestone that de-risks the trial timeline and confirms the company is on track to report topline overall survival data as early as the end of 2026. The trial addresses a significant unmet need in the post-PD1 setting, with an estimated 4,000 eligible HLA-A*02:01-positive patients in the US and Europe. Positive data could support a label expansion beyond the current uveal melanoma indication, substantially increasing KIMMTRAK's commercial opportunity. The announcement follows strong Q2 2026 results showing 18% revenue growth and near-breakeven performance, reinforcing the company's execution. Investors will now focus on the upcoming data readout, which is the primary value driver for the stock.
At the time of this announcement, IMCR was trading at $32.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $27.56 to $40.71. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.